Drugs / CD19.CAR-multiVST
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03768310 | Jun 2022 → Aug 2025 | acute lymphoblastic leukemia | Baylor College of Medicine | Withdrawn | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19.CAR-multiVST | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03768310 ↗ |
| Action | Deplete | “they kill CD19+ tumor cells” NCT03768310 ↗ |
| Modality | Cell therapy | “These CD19 chimeric receptor multivirus specific T cells are an investigational product not approved by the Food and Drug Administration.” NCT03768310 ↗ |
| Route | Intravenous | “CD19.CAR-multiVSTs will be given by intravenous injection” NCT03768310 ↗ |